Skip to main content
. 2020 Nov 7;9(22):e017364. doi: 10.1161/JAHA.120.017364

Figure 2. Inpatient mortality rates by renin‐angiotensin‐aldosterone system inhibitor use before admission for coronavirus disease 2019 (COVID‐19).

Figure 2

RAASi indicates renin‐angiotensin‐aldosterone system inhibitor.